Savara Inc. $SVRA Position Boosted by Geode Capital Management LLC

Geode Capital Management LLC lifted its holdings in Savara Inc. (NASDAQ:SVRA) by 5.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,970,183 shares of the company’s stock after purchasing an additional 147,946 shares during the period. Geode Capital Management LLC owned about 1.72% of Savara worth $6,773,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new position in Savara in the second quarter worth approximately $69,000. Emerald Mutual Fund Advisers Trust boosted its stake in shares of Savara by 8.5% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 2,186,404 shares of the company’s stock worth $4,985,000 after acquiring an additional 171,948 shares in the last quarter. Emerald Advisers LLC grew its holdings in shares of Savara by 14.4% in the 2nd quarter. Emerald Advisers LLC now owns 3,534,368 shares of the company’s stock worth $8,058,000 after acquiring an additional 444,155 shares during the last quarter. May Hill Capital LLC acquired a new position in shares of Savara in the 2nd quarter worth $32,000. Finally, Farther Finance Advisors LLC raised its position in shares of Savara by 17.6% during the second quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock worth $87,000 after purchasing an additional 5,687 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Savara Price Performance

Shares of SVRA opened at $6.50 on Friday. The business’s 50-day moving average is $4.34 and its 200-day moving average is $3.30. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.65 and a quick ratio of 7.65. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -12.26 and a beta of 0.23. Savara Inc. has a fifty-two week low of $1.89 and a fifty-two week high of $6.61.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Equities research analysts expect that Savara Inc. will post -0.45 EPS for the current fiscal year.

Analyst Ratings Changes

SVRA has been the subject of a number of recent analyst reports. Citizens Jmp decreased their price target on Savara from $11.00 to $10.00 and set a “market outperform” rating for the company in a research report on Thursday, November 13th. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a report on Wednesday, October 8th. Guggenheim lifted their target price on shares of Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. Finally, HC Wainwright boosted their price target on shares of Savara from $5.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Savara has an average rating of “Moderate Buy” and an average price target of $8.29.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.